7JN Stock Overview
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Poolbeg Pharma PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.09 |
| 52 Week High | UK£0.11 |
| 52 Week Low | UK£0.037 |
| Beta | 0 |
| 1 Month Change | 55.17% |
| 3 Month Change | 36.36% |
| 1 Year Change | 4.65% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7JN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -1.3% | -1.1% |
| 1Y | 4.7% | 1.9% | -11.6% |
Return vs Industry: 7JN exceeded the German Pharmaceuticals industry which returned 1.9% over the past year.
Return vs Market: 7JN exceeded the German Market which returned -11.6% over the past year.
Price Volatility
| 7JN volatility | |
|---|---|
| 7JN Average Weekly Movement | 18.3% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7JN is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: 7JN's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 7 | Jeremy Skillington | https://www.poolbegpharma.com |
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.
Poolbeg Pharma PLC Fundamentals Summary
| 7JN fundamental statistics | |
|---|---|
| Market Cap | €50.73m |
| Earnings (TTM) | -€3.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-14.3x
P/E RatioIs 7JN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7JN income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£3.11m |
| Earnings | -UK£3.11m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0062 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7JN perform over the long term?
See historical performance and comparison